| Literature DB >> 35407374 |
Alexander Taschner1, Barbara Kabon1,2, Markus Falkner von Sonnenburg1, Alexandra Graf3, Nikolas Adamowitsch1, Melanie Fraunschiel4, Edith Fleischmann1,2, Christian Reiterer1,2.
Abstract
Perioperative stress is associated with increased sympathetic activity that leads to increases in heart rate and blood pressure, which are associated with the development of perioperative myocardial ischemia. In healthy volunteers, it was shown that the administration of supplemental oxygen attenuated sympathetic nerve activity and subsequently led to lower plasma catecholamine concentrations. We therefore tested the hypothesis that perioperative supplemental oxygen attenuates sympathetic nerve in patients at risk for cardiovascular complications undergoing major abdominal surgery. We randomly assigned 81 patients to receive either 80% or 30% inspired oxygen concentration throughout surgery and the first two postoperative hours. We assessed noradrenaline, adrenaline, and dopamine plasma concentrations before the induction of anesthesia, two hours after surgery and on the third postoperative day. There was no significant difference in postoperative noradrenaline (effect estimated: -41.5 ng·L-1, 95%CI -134.3, 51.2; p = 0.38), adrenaline (effect estimated: 11.2 ng·L-1, 95%CI -7.6, 30.1; p = 0.24), and dopamine (effect estimated: -1.61 ng·L-1, 95%CI -7.2, 3.9; p = 0.57) concentrations between both groups. Based on our results, it seems unlikely that supplemental oxygen influences endogenous catecholamine release in the perioperative setting.Entities:
Keywords: MINS; cardiovascular risk; catecholamines; major abdominal surgery; supplemental oxygen
Year: 2022 PMID: 35407374 PMCID: PMC9000182 DOI: 10.3390/jcm11071767
Source DB: PubMed Journal: J Clin Med ISSN: 2077-0383 Impact factor: 4.241
Figure 1Patient Flow Diagram; Design and Form in Accordance with the 2010 CONSORT Guidelines [13].
Summary characteristics are presented as counts, percentages of patients, and median (25th quartile; 75th quartile). BMI, body mass index; ASA, American Society of Anesthesiologists physical status; ACI, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; CRP, C-reactive protein; NT-proBNP, N-terminal brain natriuretic peptide.
| Patient Characteristics | ||||
|---|---|---|---|---|
| 80% Oxygen | 30% Oxygen | |||
|
| 75 | (70; 78) | 73 | (69; 77) |
| Height, cm | 170 | (167; 175) | 174 | (168; 179) |
| Weight, kg | 80 | (72; 88) | 84 | (77; 92) |
| BMI, kg·m−2 | 26.8 | (24.1; 29.8) | 27.6 | (25.2; 29.9) |
| Sex, | ||||
| Women | 15 | (36.7) | 9 | (22.5) |
| Men | 26 | (63.3) | 31 | (77.5) |
| ASA physical status, | ||||
| II | 13 | (36.6) | 16 | (40) |
| III | 28 | (63.4) | 24 | (60) |
| Comorbidities, | ||||
| Hypertension | 39 | (95.1) | 36 | (90.0) |
| Coronary artery disease | 9 | (21.9) | 8 | (20.0) |
| Peripheral artery disease | 6 | (14.6) | 5 | (12.5) |
| Stroke | 5 | (12.2) | 4 | (10.0) |
| Congestive heart failure | 3 | (7.3) | 3 | (7.5) |
| Transient ischemic attack | 1 | (2.4) | 6 | (15.0) |
| Insulin use | 13 | (31.7) | 12 | (30.0) |
| Long-term medication, | ||||
| Beta blockers | 17 | (41.5) | 16 | (40.0) |
| ACI/ARB | 24 | (58.5) | 21 | (52.5) |
| Diuretics | 12 | (29.3) | 6 | (15.0) |
| Statins | 20 | (48.8) | 18 | (45.0) |
| Acetylsalicylic acid | 2 | (4.9) | 3 | (7.5) |
| Oral anticoagulant | 18 | (43.9) | 15 | (37.5) |
| Alpha 2 agonist | 1 | (2.4) | 2 | (5.0) |
| Type of Surgery, (%) | ||||
| Hepatobiliary | 8 | (19.5) | 7 | (17.5) |
| Colorectal | 9 | (22.0) | 8 | (20.0) |
| Pancreatic | 6 | (14.6) | 3 | (7.5) |
| Urological | 12 | (29.3) | 19 | (47.5) |
| Other | 6 | (14.6) | 3 | (7.5) |
| Laboratory parameters | ||||
| CRP, mg·dL−1 | 0.33 | (0.19; 1.43) | 0.26 | (0.12; 0.58) |
| Creatinine, mg·dL−1 | 0.9 | (0.8; 1.0) | 0.9 | (0.8; 1.1) |
| Leukocytes, G·L−1 | 6.61 | (5.42; 8.60) | 6.58 | (5.03; 8.07) |
| NT-proBNP, pg·mL−1 | 280 | (97; 533) | 128 | (69; 391) |
| Troponin T, ng·L−1 | 14 | (11; 22) | 15 | (9; 22) |
Summary characteristics of perioperative variables are presented as medians (25th quartile; 75th quartile). All p-values are for two-tailed Mann-Whitney U tests or chi-square tests according to the distribution of data. etSevo, end-tidal Sevoflurane concentration; FiO2, fraction of inspired oxygen; etCO2, end-tidal carbon dioxide concentration; HR, heart rate; MAP mean arterial pressure; SV, stroke volume; CO, cardiac output; CVP, central venous pressure; pO2, oxygen partial pressure; pCO2, carbon dioxide partial pressure; SpO2, peripheral oxygen saturation; BE, base excess; Hb, hemoglobin; VAS, visual analog scale.
| Perioperative Variables | |||||
|---|---|---|---|---|---|
| 80% Oxygen | 30% Oxygen | ||||
|
| |||||
| Duration of anesthesia, min | 264 | (191; 403) | 215 | (177; 287) | 0.06 |
| Duration of surgery, min | 207 | (134; 329) | 152 | (129; 233) | 0.17 |
|
| |||||
| Crystalloid, mL | 2237 | (1262; 3538) | 1936 | (1396; 2696) | 0.41 |
| Blood loss, mL | 200 | (0; 500) | 200 | (0; 500) | 0.78 |
| Urine output, mL | 245 | (150; 400) | 225 | (285; 400) | 0.83 |
|
| |||||
| Fentanyl, mcg | 1100 | (863; 1488) | 1050 | (800; 1500) | 0.60 |
| Propofol, mg | 145 | (70; 160) | 150 | (100; 200) | 0.15 |
| Phenylephrine, mg | 0.25 | (0.10; 0.58) | 0.20 | (0.08; 0.52) | 0.56 |
| Noradrenaline, mg | 0.0 | (0.0; 1.0) | 0.0 | (0.0; 0.3) | 0.10 |
| etSevo, % | 1.3 | (1.0; 1.5) | 1.2 | (0.7; 1.4) | 0.18 |
| FiO2, % | 81 | (80; 81) | 32 | (31; 68) | |
| etCO2, mmHg | 35 | (34; 36) | 34 | (32; 36) | 0.18 |
| Core temp, °C | 36.2 | (35.9; 36.8) | 36.4 | (36.2; 36.9) | 0.55 |
|
| |||||
| HR, beats·min−1 | 62 | (58; 69) | 73 | (62; 84) | 0.59 |
| MAP, mmHg | 79 | (74; 90) | 91 | (85; 95) | 0.42 |
| SV, mL | 77 | (55; 81) | 52 | (30; 67) | 0.22 |
| CO, L·min−1 | 4.7 | (3.7; 5.4) | 3.3 | (1.9; 4.5) | 0.12 |
| CVP, mmHg | 12 | (8; 15) | 11 | (8; 20) | 0.69 |
|
| |||||
| pO2, mmHg | 158 | (112; 195) | 91 | (75; 155) | <0.05 |
| pCO2, mmHg | 43 | (39; 52) | 49 | (46; 60) | 0.50 |
| SpO2, | 100 | (99; 100) | 98 | (97; 99) | <0.001 |
| pH | 7.34 | (7.28; 7.38) | 7.31 | (7.25; 7.34) | 0.33 |
| BE | −1.9 | (−4.6; −0.7) | −1.2 | (−3.3; −0.1) | 0.25 |
| Hb, g·dL−1 | 11.8 | (10.4; 12.5) | 13.4 | (11.1; 13.9) | 0.31 |
| Lactate, mmol·L−1 | 0.8 | (0.6; 1.0) | 1.6 | (0.9; 2.3) | 0.53 |
| Glucose, mg·dL−1 | 163 | (150; 184) | 155 | (123; 175) | 0.31 |
|
| |||||
|
| |||||
| HR, beats·min−1 | 75 | (60; 88) | 82 | (64; 90) | 0.41 |
| MAP, mmHg | 86 | (75; 103) | 109 | (98; 122) | <0.001 |
| SpO2, % | 99 | (97; 99) | 98 | (97; 99) | 0.11 |
| VAS | 2 | (0; 4) | 2 | (0; 4) | 0.88 |
|
| |||||
| Dexamethasone, | 29 | (70.7) | 35 | (87.5) | 0.10 |
| PONV, | 4 | (9.8) | 5 | (12.5) | 0.74 |
| Ondansetron, | 10 | (24.4) | 12 | (30.0) | 0.62 |
| Amount per capita, mg | 4 | (4; 5) | 4 | (4; 5) | 0.84 |
| Droperidol, | 2 | (4.9) | 3 | (7.5) | 0.68 |
| Amount per capita, mg | 1.25 | (1.25; 1.25) | 1.25 | (1.25; 1.25) | 1.00 |
|
| |||||
| Fluid, mL (a) | 10,400 | (7417; 12,525) | 9471 | (7013; 11,526) | 0.58 |
| Piritramide, mg (b) | 12.0 | (4.5; 22.0) | 8.3 | (3.0; 21.8) | 0.65 |
(a) overall amount of fluid administered during the first 72 h after surgery. (b) overall amount of piritramide administered during the first 72 h after surgery.
Figure 2Plots showing the perioperative course of plasma noradrenaline (a), adrenaline (b), and dopamine (c) concentrations between patients who received 80% oxygen (blue) and patients who received 30% oxygen (red). Each circle represents one patient at each timepoint.
Plasma catecholamine concentrations at each timepoint are presented as median (25th quartile; 75th quartile). All p-values are for two-tailed Mann-Whitney U tests.
| Plasma Catecholamine Concentrations | |||||
|---|---|---|---|---|---|
| 80% Oxygen | 30% Oxygen | ||||
|
| |||||
| Baseline | 247 | (147; 443) | 259 | (170; 369) | 0.20 |
| 2 h postoperative | 757 | (447; 1240) | 494 | (318; 864) | 0.13 |
| Postoperative day 3 | 560 | (384; 827) | 493 | (313; 730) | 0.89 |
| Adrenaline, ng·L−1 | |||||
| Baseline | 27 | (16; 43) | 25 | (14; 69) | 0.59 |
| 2 h postoperative | 187 | (70; 539) | 193 | (74; 444) | 0.86 |
| Postoperative day 3 | 36 | (18; 49) | 43 | (23; 75) | 0.17 |
| Dopamine, ng·L−1 | |||||
| Baseline | 0 | (0; 19) | 0 | (0; 15) | 0.66 |
| 2 h postoperative | 34 | (19; 52) | 19 | (0; 35) | 0.10 |
| Postoperative day 3 | 23 | (0; 37) | 0 | (0; 85) | 0.92 |
Plasma noradrenaline, adrenaline, and dopamine concentrations between patients with MINS and patients with no MINS are presented as median (25th quartile; 75th quartile). All p-values are for two-tailed Mann-Whitney U tests.
| Post-Hoc Analysis | |||||
|---|---|---|---|---|---|
| MINS | No MINS | ||||
|
| |||||
| Baseline | 233 | (121; 415) | 259 | (166; 380) | |
| 2 h postoperative | 672 | (365; 990) | 501 | (349; 927) | |
| Postoperative day 3 | 505 | (400; 809) | 531 | (311; 795) | |
| Maximum | 782 | (508; 1040) | 855 | (597; 1164) | 0.48 |
| Adrenaline, ng·L−1 | |||||
| Baseline | 31 | (16; 48) | 21 | (15; 56) | |
| 2 h postoperative | 164 | (83; 585) | 193 | (67; 442) | |
| Postoperative day 3 | 38 | (18; 87) | 40 | (22; 66) | |
| Maximum | 171 | (113; 571) | 211 | (75; 438) | 0.72 |
| Dopamine, ng·L−1 | |||||
| Baseline | 0 | (0; 19) | 0 | (0; 0) | |
| 2 h postoperative | 31 | (0; 61) | 23 | (15; 36) | |
| Postoperative day 3 | 16 | (0; 53) | 22 | (0; 67) | |
| Maximum | 39 | (11; 68) | 36 | (17; 71) | 0.94 |